Nigel DawsonNigel Dawson
|
 |
One key resistance mechanism is the ability to destroy the antibiotic through utilization of one or more types of beta-lactamase. The discovery and development of modified Penicillin VK (V-Cillin K)- and cephalosporin-derived beta-lactamase inhibitors.While beta-lactam antibiotics remain among the most commonly prescribed pharmaceutical products, their effectiveness is currently threatened by the development of bacterial resistance. In order to select antibiotic-resistant organisms, the antibiotic must be able to eradicate the susceptible population. Other antibiotics achieve salivary concentrations in the range 10-30% of serum concentrations (erythromycin, clindamycin, doxycycline (Doryx)and rifampicin), and are also able to eradicate the antibiotic-susceptible population. To diminish the risk, the antibiotics should be dosed in order to obtain inhibitory quotients (maximal serum concentration/MIC ratios) >/ chemistry jobs usa antibiotic 4, which depends not only on the antibiotic concentration achieved but also on the lack of highly resistant organisms. Pharmacodynamic and kinetic basis for the selection of pneumococcal resistance in the upper respiratory tract.The oropharynx is both the reservoir where antibiotic-resistant antibiotic Streptococcus pneumoniae strains are selected and the focus for further spread of these organisms. Pneumoniae, and although their saliva concentrations are very low, there may be enough to eradicate the majority of beta-lactam-sensitive strains. Many beta-lactam antibiotics are very active against antibiotics S. Useful synthetic methodology will be described, which simplifies the large scale production of many known inhibitors and which allows the rapid preparation of libraries of prospective inhibitors.. How an antibiotic acts on oropharyngeal flora is not fully understood, although data on salivary antibiotic concentrations could be useful for establishing some correlation. Only antibiotics for which there are no highly resistant pneumococcal strains, for instance some beta-lactams administered at very high dose and for a short course, are associated with a lower risk of antibiotic resistance selection. An effective countermeasure is to employ a combination product, consisting of both a beta-lactam antibiotic and a beta-lactamase inhibitor. This review will detail our research, directed toward the development of a useful broad-spectrum beta-lactamase inhibitor. In the process, we have discovered new inhibitors capable of simultaneously inactivating class A, C, and D beta-lactamase, produced conjugate siderophore/beta-lactamase inhibitors, and explored the SAR's of tunable, cephalosporin-derived beta-lactamase inactivators. Antibiotics achieving higher salivary concentrations (>/ 40% of the serum levels) are not very active against S. Unfortunately, currently available inhibitors narrowly target only class A beta-lactamases. Pneumoniae (Ciprofloxacin (Cipro)) or are able to eradicate antibiotic-sensitive and-intermediate strains (clarithromycin, azithromycin and telithromycin).
|